Pulmonary Hypertension: What It Is and Why Early Diagnosis Matters
Pulmonary hypertension symptoms and treatment are increasingly relevant in India, where the condition is often diagnosed late due to its gradual, non-specific onset. Pulmonary hypertension (PH) is a serious condition in which blood pressure within the arteries of the lungs becomes abnormally elevated, forcing the right side of the heart to work harder than normal. Over time, this strain can lead to right heart failure. At Pulmo Vista, Greater Kailash, New Delhi, our pulmonology team — with 10+ years of experience in respiratory and critical care — provides structured evaluation and management for patients with suspected or confirmed pulmonary hypertension.
- Definition: Mean pulmonary arterial pressure (mPAP) ≥20 mmHg at rest, measured by right heart catheterisation.
- Classification: Five WHO groups based on underlying cause — arterial, venous, hypoxic, thromboembolic, and miscellaneous.
- Distinction from systemic hypertension: Systemic hypertension (e.g. 140/90 mmHg) affects the body’s general circulation; pulmonary hypertension specifically affects the lung vasculature and right heart — they are separate conditions requiring different management.
- Prevalence context: PH is underdiagnosed in India, partly because early symptoms overlap with common respiratory and cardiac conditions.
- Prognosis: Early diagnosis and targeted therapy significantly improve quality of life and slow disease progression, though PH is generally not curable in its arterial form.
Tip: Pulmonary hypertension is not the same as high blood pressure (systemic hypertension). A normal blood pressure reading does not rule out pulmonary hypertension — specialist evaluation is required.
Clinical Features and Early Warning Signs of Pulmonary Hypertension
The first symptom of pulmonary hypertension is typically unexplained breathlessness on exertion — often dismissed as deconditioning or anaemia. As the disease progresses, symptoms become more pronounced and disabling. Recognising the full clinical picture is essential for timely referral to a pulmonology specialist.
| Symptom | Stage Typically Seen | Clinical Note |
|---|---|---|
| Exertional dyspnoea | Early (WHO FC II) | Most common first symptom; breathlessness during routine activity |
| Fatigue and weakness | Early to moderate | Reduced cardiac output limits oxygen delivery to muscles |
| Chest pain or pressure | Moderate (WHO FC III) | Right ventricular ischaemia; can mimic angina |
| Syncope or near-syncope | Moderate to advanced | Indicates severely reduced cardiac output; requires urgent review |
| Palpitations | Variable | Arrhythmias secondary to right heart strain |
| Peripheral oedema | Advanced (WHO FC IV) | Ankle and leg swelling due to right heart failure |
| Cyanosis | Advanced | Bluish discolouration of lips/fingertips; severe hypoxaemia |
| Haemoptysis | Variable | Coughing blood; more common in certain PH subtypes |
Warning: Syncope (fainting) during or after physical activity is a red-flag symptom of advanced pulmonary hypertension. Seek immediate medical evaluation — do not wait for a routine appointment.
Causes of Pulmonary Hypertension and Key Risk Factors
Pulmonary hypertension in India arises from a wide range of underlying conditions. Identifying the cause is critical because treatment strategy differs significantly across the five WHO groups. Common causes and risk factors include:
- Pulmonary arterial hypertension (PAH, Group 1): May be idiopathic, heritable, or associated with connective tissue disease (e.g. scleroderma), congenital heart disease, HIV, or portal hypertension.
- Left heart disease (Group 2): Heart failure with reduced or preserved ejection fraction; mitral or aortic valve disease — a common cause of PH globally.
- Chronic lung disease and/or hypoxia (Group 3): COPD, interstitial lung disease, sleep-disordered breathing, and high-altitude exposure — particularly relevant in India.
- Chronic thromboembolic PH (CTEPH, Group 4): Unresolved blood clots in the pulmonary arteries following pulmonary embolism.
- Miscellaneous mechanisms (Group 5): Haematological disorders, systemic conditions, metabolic diseases.
- Additional risk factors: Female sex (PAH is more common in women), obesity, family history, use of certain appetite suppressants, and rheumatological conditions.
Patients with COPD or chronic lung infections are at elevated risk of developing secondary pulmonary hypertension and should be monitored accordingly. Patients with known allergy-related respiratory conditions should also discuss pulmonary hypertension risk with their specialist if symptoms progress.
Pulmonary Hypertension Diagnosis: Tests and the Gold Standard
The gold standard for diagnosing pulmonary hypertension is right heart catheterisation (RHC), which directly measures mean pulmonary arterial pressure (mPAP). However, diagnosis follows a stepwise pathway — non-invasive tests are used first to raise clinical suspicion before RHC is performed. At Pulmo Vista, advanced respiratory diagnostics are available under one roof to support this pathway.
- Echocardiography (Echo): First-line non-invasive screening tool; estimates pulmonary artery systolic pressure and assesses right ventricular function.
- Pulmonary Function Tests (PFT): Identifies underlying obstructive or restrictive lung disease contributing to PH. Pulmo Vista operates a complete PFT system for comprehensive assessment.
- Chest X-ray: May show enlarged pulmonary arteries or right heart enlargement.
- ECG: Detects right ventricular strain patterns.
- CT Pulmonary Angiography (CTPA): Rules out CTEPH and evaluates pulmonary vasculature; CT-guided procedures are available at Pulmo Vista.
- Ventilation-Perfusion (V/Q) Scan: Preferred for detecting CTEPH when CTPA is inconclusive.
- 6-Minute Walk Test (6MWT): Functional assessment of exercise capacity; used for staging and monitoring treatment response.
- Right Heart Catheterisation (RHC): Definitive diagnostic test; confirms diagnosis and guides vasoreactivity testing for treatment selection.
- Sleep Study / Polysomnography: Indicated when sleep-disordered breathing is suspected as a contributing cause. Pulmo Vista offers a home-based sleep study for patient convenience.
- Lung Ultrasound and DVT Screening: Available at Pulmo Vista to assess for thromboembolic causes and right heart changes.
Tip: An echocardiogram showing elevated estimated pulmonary pressures is not a diagnosis of pulmonary hypertension — it is an indication for further specialist evaluation, including right heart catheterisation.
Pulmonary Hypertension Treatment Options in India
Treatment of pulmonary hypertension in India depends on the WHO group, functional class, and underlying cause. Group 1 (pulmonary arterial hypertension) has a range of targeted pharmacological therapies available. Other groups are managed primarily by treating the underlying condition. The following table summarises the main treatment approaches:
| Treatment Category | Examples | Applicable PH Group | Key Consideration |
|---|---|---|---|
| Supportive therapy | Diuretics, oxygen therapy, anticoagulation | All groups | Manages symptoms; does not reverse vascular remodelling |
| Calcium channel blockers | Amlodipine, nifedipine | Group 1 — vasoreactive patients only | Reserved for patients who respond positively to vasoreactivity testing during RHC |
| Endothelin receptor antagonists (ERAs) | Ambrisentan, bosentan, macitentan | Group 1 | Oral; reduces pulmonary vascular resistance |
| PDE-5 inhibitors | Sildenafil, tadalafil | Group 1 | Widely available in India; improves exercise capacity |
| Prostacyclin analogues / agonists | Iloprost, treprostinil, selexipag | Group 1 (advanced, WHO FC III–IV) | Inhaled, subcutaneous, or oral forms available |
| Pulmonary endarterectomy (PEA) | Surgical removal of clot material | Group 4 (CTEPH — operable) | May resolve PH in suitable surgical candidates |
| Balloon pulmonary angioplasty (BPA) | Catheter-based intervention | Group 4 (inoperable CTEPH) | Emerging option at select Indian centres |
| Lung transplantation | Single or bilateral lung transplant | Group 1 (refractory) | Last resort; limited availability in India |
| PAP therapy / respiratory support | CPAP, BiPAP, oxygen | Group 3 (sleep/hypoxia-related) | Pulmo Vista offers PAP therapy and polysomnography interpretation |
Lifestyle modifications — including supervised exercise, weight management, and avoidance of high altitude — are recommended alongside pharmacological therapy. Reducing obesity-related hypoxia (particularly in Group 3 PH) can help lower pulmonary pressures. Patients are also encouraged to explore pulmonary physiotherapy and rehabilitation as part of a comprehensive management plan.
When to See a Pulmonologist for Pulmonary Hypertension
Do not wait for symptoms to become severe. Seek specialist evaluation if you experience any of the following:
- Breathlessness on exertion that has worsened progressively over 4 or more weeks without a clear cause.
- Unexplained fatigue that limits daily activities for more than 2–3 weeks.
- Any episode of fainting or near-fainting during or immediately after physical activity.
- Chest pain or palpitations occurring alongside breathlessness.
- Ankle or leg swelling that is new or worsening, especially without a cardiac or renal diagnosis.
- An echocardiogram report suggesting elevated pulmonary artery pressures — even if you feel relatively well.
- Known risk conditions: connective tissue disease, congenital heart disease, chronic liver disease, HIV, or a prior pulmonary embolism.
- Existing COPD or interstitial lung disease with a sudden or unexplained decline in exercise tolerance.
Warning: Pulmonary hypertension is frequently misdiagnosed as asthma or deconditioning in its early stages. If symptoms persist despite standard treatment for another condition, request a specialist review specifically for pulmonary hypertension.
Pulmonary Hypertension Care at Pulmo Vista, Greater Kailash
Pulmo Vista, Greater Kailash, New Delhi offers a structured, diagnostics-led approach to pulmonary hypertension — from initial screening through to ongoing management. With 10+ years of experience in respiratory and critical care, the clinic brings together the investigative tools and clinical expertise needed to evaluate PH accurately and efficiently.
- Complete Pulmonary Function Testing (PFT): Identifies underlying lung disease contributing to PH.
- Lung Ultrasound and DVT Screening: Evaluates right heart changes and thromboembolic risk non-invasively.
- Sleep Study and Polysomnography: Detects sleep-disordered breathing as a contributing cause; home-based study available.
- PAP Therapy and Respiratory Support: For patients with hypoxia-related PH (Group 3).
- Bronchoscopy and EBUS: Where indicated for differential diagnosis of underlying lung pathology.
- ICU and Critical Care Expertise: For patients presenting with advanced right heart failure or haemodynamic compromise.
- Integrated Pulmonary Rehabilitation: Supervised exercise and respiratory care as part of long-term management.
Patients with recurrent lung infections or post-COVID respiratory complications are also assessed for secondary pulmonary hypertension. For patients recovering from COVID-19, post-COVID physiotherapy is available as part of a comprehensive respiratory recovery programme.
Book a consultation at Pulmo Vista
Use the booking form on this page, or reach out directly:
Call: 8448046304
WhatsApp: 8448046304